Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,251 shares of the biopharmaceutical company’s stock after selling 512 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Alnylam Pharmaceuticals were worth $7,256,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas grew its holdings in shares of Alnylam Pharmaceuticals by 3.2% in the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock valued at $11,872,000 after purchasing an additional 1,123 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 33.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock valued at $31,238,000 after purchasing an additional 23,749 shares during the last quarter. Simon Quick Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $222,000. Strs Ohio acquired a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $7,781,000. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several analyst reports. Evercore ISI increased their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. HC Wainwright set a $570.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group upped their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $482.17.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the transaction, the executive vice president directly owned 27,438 shares of the company’s stock, valued at $12,403,347.90. The trade was a 4.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 82,346 shares of company stock valued at $37,530,942. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.1%

NASDAQ ALNY opened at $449.16 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $59.34 billion, a price-to-earnings ratio of -181.85 and a beta of 0.30. The firm has a 50 day simple moving average of $458.80 and a 200-day simple moving average of $383.97. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.